Abstract
PsA is a chronic, inflammatory, musculoskeletal disease affecting approximately one quarter of people with the skin condition psoriasis [1, 2]. PsA is a highly heterogeneous disease, encompassing diverse musculoskeletal manifestations or ‘domains’ resulting from disease activity in different tissues. These include peripheral arthritis, spondylitis (axial inflammation), dactylitis (inflammation of the whole digit) and enthesitis (inflammation where a tendon, ligament or joint capsule insert to the bone). Unlike RA, there is a significant variability in clinical presentation of PsA. Individuals with PsA may have different domains involved and drugs have different levels of effectiveness on each domain. It is therefore essential that clinical guidelines for the treatment selection in PsA include disease phenotype and differential effect of medication.
Original language | English |
---|---|
Pages (from-to) | e255-e266 |
Number of pages | 12 |
Journal | Rheumatology (Oxford, England) |
Volume | 61 |
Issue number | 9 |
Early online date | 31 May 2022 |
DOIs | |
Publication status | Published - 1 Sept 2022 |
Bibliographical note
We gratefully acknowledge the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the members of their Treatment Recommendations working group who shared extracted data on treatment RCTs for this project.Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript. Expenses for travel were paid by the British Society for Rheumatology.
Data Availability Statement
All relevant data produced during the guideline development process are presented in this manuscript or in the accompanying supplementary material.Keywords
- biologics
- dactylitis
- enthesitis
- guideline
- management
- PsA
- psoriasis
- recommendations
- targeted synthetic DMARDs
- treatment